P
Paul DiSilvestro
Researcher at Brown University
Publications - 146
Citations - 9916
Paul DiSilvestro is an academic researcher from Brown University. The author has contributed to research in topics: Gynecologic oncology & Ovarian cancer. The author has an hindex of 33, co-authored 136 publications receiving 6635 citations. Previous affiliations of Paul DiSilvestro include Harvard University & Seattle Cancer Care Alliance.
Papers
More filters
Journal ArticleDOI
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung Gie Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Cara Mathews,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +20 more
TL;DR: The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression‐free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olAParib than with placebo.
Journal ArticleDOI
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Richard G. Moore,D. Scott McMeekin,A.K. Brown,Paul DiSilvestro,M. Craig Miller,W. Jeffrey Allard,Walter H. Gajewski,Robert J. Kurman,Robert C. Bast,Steven J. Skates +9 more
TL;DR: An algorithm utilizing HE4 and CA125 successfully classified patients into high and low risk groups with 93.8% of EOC correctly classified as high risk, which can be used to effectively triage patients to centers of excellence.
Journal ArticleDOI
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
Richard G. Moore,A.K. Brown,M. Craig Miller,Steven J. Skates,W. Jeffrey Allard,Thorsten Verch,Margaret M. Steinhoff,Geralyn Messerlian,Paul DiSilvestro,Cornelius O. Granai,Robert C. Bast +10 more
TL;DR: As a single tumor marker, HE4 had the highest sensitivity for detecting ovarian cancer, especially Stage I disease and combined CA125 and HE4 is a more accurate predictor of malignancy than either alone.
Journal ArticleDOI
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist,Maria I. Harrell,Mark F. Brady,Tom Walsh,Ming K. Lee,Suleyman Gulsuner,Sarah S. Bernards,Silvia Casadei,Qian Yi,Robert A. Burger,John K. Chan,Susan A. Davidson,Robert S. Mannel,Paul DiSilvestro,Heather A. Lankes,Nilsa C. Ramirez,Mary Claire King,Elizabeth M. Swisher,Michael J. Birrer +18 more
TL;DR: To determine the frequency and importance of germline mutations in cancer-associated genes in OC, a study population of 1915 women with OC and available germline DNA was identified and mutations were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC).
Journal ArticleDOI
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman,Gini F. Fleming,Mark F. Brady,Elizabeth M. Swisher,Karina Dahl Steffensen,Michael Friedlander,Aikou Okamoto,Kathleen N. Moore,Noa Ben-Baruch,Theresa L. Werner,N.G. Cloven,Ana Oaknin,Paul DiSilvestro,Mark A. Morgan,Joo-Hyun Nam,Charles A. Leath,Shibani Nicum,Andrea R. Hagemann,Ramey D. Littell,David Cella,Sally Baron-Hay,Jesús García-Donas,Mika Mizuno,Katherine M. Bell-McGuinn,Danielle Sullivan,Bruce A. Bach,Sudipta Bhattacharya,Christine K. Ratajczak,Peter Ansell,Minh H. Dinh,Carol Aghajanian,Michael A. Bookman +31 more
TL;DR: Across all trial populations, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliporib maintenance therapy led to significantly longer progression-free survival than carboplati plus pac Litaxel induction therapy alone.